Compare Citius Pharmaceuticals Inc (CTXR) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Microchip Technology Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Microchip Technology Inc. trades at $87.97 (market cap $47.30B). The key difference: Microchip Technology Inc. is far larger — about 3230.9× Citius Pharmaceuticals Inc's market cap, and Microchip Technology Inc. pays a 2.09% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MCHP | |
|---|---|---|
Market Cap | $14.64M | $47.30B |
Sector | Health | Technology |
52-Week High | $1.82 | $102.97 |
52-Week Low | $0.53 | $49.02 |
Enterprise Value | $10.86M | $52.60B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Microchip Technology (MCHP) trades at $84.23, down 4.92% in the last session, with a bearish technical signal and support near $81. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, while revenue declined to $4.40B. Analyst consensus remains strongly bullish with a $113.33 price target, supported by positive news on AI and aerospace demand.
MCHP faces near-term pressure from weak profitability and high debt, but long-term growth is supported by AI, data center, and aerospace exposure. Risks include cyclical semiconductor demand and execution challenges, yet institutional sentiment and recent product launches suggest potential recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
